




PHARMACEUTICAL 2019

ELI LILLY & Co
Rank 213 of 363





RealRate

PHARMACEUTICAL 2019

ELI LILLY & Co
Rank 213 of 363



The relative strengths and weaknesses of ELI LILLY & Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI LILLY & Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 80% points. The greatest weakness of ELI LILLY & Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 114% points.

The company's Economic Capital Ratio, given in the ranking table, is 57%, being 21% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	20,549,600
Cost of Goods Sold	6,430,000
Intangible Assets	7,868,500
Liabilities, Current	11,888,100
Liabilities, Non-Current	21,111,200
Other Assets	6,570,800
Other Compr. Net Income	83,600
Other Expenses	2,954,800
Other Liabilities	0
Other Net Income	0
Other Revenues	24,555,700
Property and Equipment	8,919,500
Research and Development	5,307,100
Selling, General and Administrative Expense	6,631,800

Output Variable	Value in 1000 USD
Assets	43,908,400
Liabilities	32,999,300
Expenses	21,323,700
Revenues	24,555,700
Stockholders Equity	10,909,100
Net Income	3,232,000
Comprehensive Net Income	3,273,800
Economic Capital Ratio	57%